Recombinant human serum albumin (rHSA)

01Overview and value chain

Markers: [EC: FDA Biologics License Application (BLA) & Novel Excipient Pathway / EU Centralised Procedure (CHMP→EC) / NMPA Biological Products Approval / CDSCO Subject Expert Committee (India) | OECD: Bio-pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)]

Recombinant human serum albumin (rHSA) replaces the 900-kDa fractionation of donor blood plasma — the only source of clinical intravenous HSA since the 1940s and a product chronically constrained by plasma supply and viral contamination risk — with biosynthetic production of the 66.5 kDa, 585-amino-acid HSA molecule in microbial or plant hosts. Three dominant expression platforms emerged by 2026: rice endosperm cell expression (Healthgen’s OryzHiExp / InVitria’s ExpressTec, both Oryza sativa-based); Pichia pastoris yeast (InVitria’s predecessors, Shilpa Medicare’s sRbumin, Provis Biolabs, Canvax — accounting for ~38.7% of the global market on yield efficiency); and Hansenula polymorpha yeast (Basic Pharma / ARTES Biotechnology). The global rHSA market stood at USD 166 million in 2025, is projected at USD 182 million in 2026 and USD 421 million by 2035 (CAGR 9.75%), with North America taking more than 35.6% share. The 2025-2026 commercial breakthrough was Healthgen Biotech’s OsrHSA injection (奥福民®) — the world’s first NMPA-approved recombinant HSA therapeutic injection (July 2025), the first globally-approved rice-derived recombinant protein drug, with a 22-centre Phase III in decompensated liver cirrhosis (PMID 40555465) and a 1-million-vial annual production capacity in Wuhan. InVitria’s Exbumin rice-derived rHSA has been the excipient in Merck’s ERVEBO Ebola vaccine since 2019 — the first FDA/EMA/PMDA approval of a rice-derived rHSA as an injectable excipient, with more than 250,000 human injections — and its Optibumin 25 (launched April 29, 2025) is the first recombinant 25% HSA available in closed-system bags for cell and gene therapy biomanufacturing. Proliant Health & Biologicals launched AlbufreeDX on June 24, 2026 — a precision-fermentation animal-free rHA for IVD/diagnostics — and Basic Pharma (NL) with ARTES Biotechnology (DE) launched a Hansenula polymorpha-expressed tag-free rHSA for the European Benelux market. India’s Shilpa Medicare became the first Indian company to complete a Phase 1 trial of rHA 20% (sRbumin®, August 2024, 62 healthy volunteers), secured CDSCO Phase III nod (November 2024), and signed an exclusive Orion Corporation (Finland) European commercialization deal via subsidiary Shilpa Biocare.

The key directions of recombinant human serum albumin are:

1. Rice endosperm expression (OsrHSA / ExpressTec / OryzHiExp): Healthgen Biotech’s OsrHSA (奥福民®) — first NMPA-approved rHSA injection (July 2025), 22-centre Phase III in decompensated liver cirrhosis, 1-million-vial annual capacity in Wuhan’s Optics Valley; InVitria’s Exbumin — the rice-derived rHSA excipient in Merck’s ERVEBO Ebola vaccine, FDA/EMA/PMDA-approved since 2019, with Optibumin 25 (launched April 29, 2025) extending the platform to 25% closed-system-bag biomanufacturing.
2. Pichia pastoris yeast expression: Shilpa Medicare’s sRbumin® rHA 20% (Phase 1 completion August 2024 in 62 healthy volunteers, CDSCO Phase III nod November 2024, Orion Europe commercialization deal via Shilpa Biocare); Provis Biolabs’ Pichia pastoris rHA (>98% purity, ISO 9001:2015 GMP); Canvax’s Pichia pastoris 20% solution — the dominant platform by market share (~38.7% on yield efficiency).
3. Hansenula polymorpha yeast expression: Basic Pharma (NL, Geleen) + ARTES Biotechnology (DE) joint Hansenula polymorpha rHSA — tag-free, >95% purity, launched at BIO-Europe (October 30, 2024); positioned for European Benelux research and biomanufacturing supply under the EU Pharmaceutical Strategy (2020).
4. Precision fermentation for diagnostics & cell culture: Proliant Health & Biologicals’ AlbufreeDX commercial launch (June 24, 2026) — precision-fermentation fungal-cell-line animal-free rHA for IVD/diagnostics, IVDR compliance; InVitria’s Cellastim S (lipid-enhanced cell culture) and Optibumin (10-25% biomanufacturing); planned expansion to AlbufreeTX (cell culture) and AlbufreeCGT (cell/gene therapy).

Sectoral value chain

[HSA gene construct / rice endosperm, Pichia, Hansenula, or fungal host] ──> [upstream expression — bioreactor or rice seed]
                                                                                              │
                                                                              (crude rHSA in biomass)
                                                                                              │
                                                                                              ▼
[finished rHSA vial / closed-system bag] <─── [fill-finish & QC] <─── [stabilizer-free formulation or lyophilization] <─── [chromatographic purification]

Value chain levels

Cross-cutting technologies of the sector:

• Rice endosperm expression platform (Rice Endosperm Expression Platform / OryzHiExp): Healthgen’s OryzHiExp and InVitria’s ExpressTec — the first plant-based recombinant expression system to support an FDA-, EMA-, and PMDA-approved injectable biologic (Exbumin in Merck’s ERVEBO Ebola vaccine, 2019); produces a stabilizer-free aggregate-depleted native-state rHSA with ~99% Cys34 thiol reduction versus ~60% in plasma HSA and a measured Kd of 2.58 μM (vs pHSA’s 7.45 μM) for drug binding affinity.
• Yeast fermentation platforms (Pichia pastoris & Hansenula polymorpha): the dominant market-share platform (~38.7% of global rHSA production on yield efficiency), with Pichia pastoris used by Shilpa Medicare, Provis Biolabs, Canvax; Hansenula polymorpha used by Basic Pharma / ARTES Biotechnology for tag-free European-sourced rHSA.
• Precision fermentation for animal-free diagnostics (Precision Fermentation rHSA): Proliant’s fungal-derived AlbufreeDX cell line for IVD-grade rHA (purity ≥98%, total protein ≥90% dry basis), targeting IVDR-compliant diagnostic and life-science applications where animal-derived pathogens must be eliminated.

02US

The US leads on commercial-scale rice-derived rHSA biomanufacturing (InVitria’s ExpressTec platform and Merck ERVEBO excipient precedent) and on diagnostic-grade precision-fermentation rHSA (Proliant Health & Biologicals), all operating under the FDA’s Biologics License Application pathway and the FDA Novel Excipient pathway.

InVitria ExpressTec rice platform, Merck ERVEBO excipient precedent, Proliant AlbufreeDX launch

• InVitria (Junction City, Kansas): the global leader in chemically-defined animal-origin-free recombinant proteins for biologics manufacturing, with an ISO 9001:2015-certified cGMP facility; its rice-based ExpressTec platform is the first plant-based recombinant expression system to support an FDA-, EMA-, and PMDA-approved injectable biologic; Exbumin (lyophilized rHSA powder, 10 g / 100 g / 1 kg / bulk) has been the excipient in Merck’s ERVEBO Ebola Zaire vaccine since 2019 — establishing the novel regulatory pathway for rice-derived rHSA as an injectable excipient across more than 250,000 human injections; Optibumin 25 (launched April 29, 2025) is the first and only recombinant 25% HSA for closed-system biomanufacturing (100 mL bags, 3-year shelf life at 2-8°C); CEO Scott Deeter presented the rHSA portfolio at IPEC Excipient World Biologics Summit (May 4-6, 2026, Nashville, TN).
• Proliant Health & Biologicals (Ankeny, Iowa; manufacturing in the US and New Zealand): a two-decade albumin manufacturer that commercially launched AlbufreeDX on June 24, 2026 — a precision-fermentation fungal-cell-line animal-free rHA (purity ≥98%, total protein ≥90% dry basis) for IVD/diagnostic applications, with planned extensions AlbufreeTX (cell culture) and AlbufreeCGT (cell/gene therapy); CEO Dr. Christopher Detzel and VP R&D Dr. Christopher Warner position AlbufreeDX for IVDR compliance and ESG-conscious IVD manufacturers.
• FDA Novel Excipient pathway: the FDA’s inactive ingredient database did not originally distinguish rHSA derivation, so Merck’s ERVEBO program — using InVitria’s rice-derived rHSA at 0.25% intramuscular injection — had to qualify rd-rHSA as a novel excipient under FDA sponsorship; this 2019 precedent, detailed in InVitria’s April 2026 ERVEBO case study, is the regulatory on-ramp every subsequent therapeutic rHSA program in the US relies on.

03CN

China holds the world’s first NMPA-approved recombinant HSA therapeutic injection (Healthgen’s OsrHSA / 奥福民®, July 2025) and the only rice-endosperm-derived rHSA mass production in commercial scale, anchored in Wuhan’s East Lake High-tech Development Zone (Optics Valley of China).

Healthgen OsrHSA first global approval, rice molecular pharming, NMPA biologics pathway

• Healthgen Biotechnology (武汉禾元生物科技股份有限公司, Wuhan, founded 2006, SSE STAR Market 688765): its OsrHSA injection (奥福民®) became the world’s first NMPA-approved rHSA therapeutic injection in July 2025 — also the first globally-approved rice-derived recombinant protein drug — backed by a multicentre, randomised, double-blind, positive-controlled Phase III trial across 22 Chinese centres in decompensated liver cirrhosis (PMID 40555465; 4:1 randomization OsrHSA:pHSA, IV 10 g or 20 g to target serum albumin 35 g/L, max 2 weeks treatment plus 2 weeks follow-up); the company reached mass production at its smart factory with an annual capacity of 1 million bottles of OsrHSA Precise, distributed via cold-chain logistics across 31 Chinese provinces and cities; four technology platforms — OryzHiExp (rice endosperm expression), OryzPur (purification), OryzDura (long-acting albumin drug), OryzNab (rice nanobody) — under a 70,000 m² cGMP facility sized for 10-ton OsrHSA bulk plus 1 million vial preparation; chairman Yang Daichang (杨代常).
• Rice molecular pharming supply chain: OsrHSA is registered with CDE 辅料备案 F2018000030 and DMF No 029648 (Type IV) for use as a pharmaceutical excipient in Chinese biologics, which positions Healthgen’s rice-derived rHSA for both direct therapeutic use (volume replacement in liver cirrhosis, burns, trauma) and as an excipient in vaccine and cell/gene therapy formulations manufactured in China — the same dual therapeutic/excipient pattern InVitria pioneered in the US with ERVEBO.
• NMPA biologics pathway: the July 2025 OsrHSA approval flowed through NMPA’s biological products approval process; the 22-centre Phase III in decompensated liver cirrhosis positions OsrHSA as the first viable NMPA-approved alternative to imported plasma-derived HSA — a strategic priority for China, which historically depends on plasma-fractionated HSA imports for trauma, burn, surgical volume replacement, and hypoalbuminemia management.

04EU

The EU hosts a Hansenula polymorpha yeast rHSA platform (Basic Pharma + ARTES Biotechnology, NL/DE) positioned under the EU Pharmaceutical Strategy (2020) for locally-anchored Benelux supply, and is the target market for India’s Shilpa Medicare Orion Corporation commercialization deal for sRbumin® rHA 20%.

Basic Pharma Hansenula platform, ARTES Biotechnology, Shilpa Biocare Orion Europe deal

• Basic Pharma (Geleen, Netherlands): produces tag-free recombinant human serum albumin (rHSA) expressed in Hansenula polymorpha yeast, in collaboration with ARTES Biotechnology (Langenfeld, Germany) — the joint product launched at BIO-Europe (October 30, 2024); positioned as the Benelux locally-anchored animal-free rHSA alternative under the EU Pharmaceutical Strategy (2020), covered in Bio-Connect (June 4, 2026); purity >95% by SDS-PAGE and HPLC, bioreactor capacity up to 50 L, non-GMP and future GMP-compatible projects; nominated for the Brilliant Business Award 2025.
• ARTES Biotechnology (Langenfeld, Germany): the joint-development partner for Basic Pharma’s rHSA, with its own Hansenula polymorpha strain platform; sells the recombinant HSA product directly (catalogue AB_FP_002, 585 amino acids, MW 66.5 kDa, animal-component-free, peptide-tag-free, lyophilized from water, purity >95% by RP-HPLC and SDS-PAGE) for research use applications (SDS-PAGE, stabilizing agent, medium component, blocking agent).
• Shilpa Biocare / Orion Corporation Europe deal: Shilpa Medicare’s wholly-owned subsidiary Shilpa Biocare Private Limited signed an exclusive European commercialization agreement with Finland-based Orion Corporation for Shilpa’s recombinant human albumin (announced Q1 FY26 / late June 2026 disclosure) — Orion gains exclusive distribution, marketing and sales rights across Europe; positions Indian-yeast-fermented rHSA as a European plasma-derived HSA alternative pending EMA regulatory filings; a separate, qualitatively noted UK player is Albumedix (Nottingham, Recombumin® product line, Sartorius subsidiary), which live 2026 sourcing named as a global key player but did not surface a specific dated 2026 commercial event.

05Leading companies and research institutes

06Tech stack and innovations

The rHSA stack rests on three orthogonal expression platforms — rice endosperm, Pichia pastoris yeast, and Hansenula polymorpha yeast — each with a distinct purity, scalability, and regulatory-acceptance profile, plus a precision-fermentation fungal route for diagnostics.

1. Rice endosperm expression (Rice Endosperm Expression Platform / OryzHiExp / ExpressTec):
   • Healthgen’s OryzHiExp and InVitria’s ExpressTec platforms express the HSA gene in rice (Oryza sativa) endosperm cells, where the seed’s natural protein-storage machinery folds and accumulates the 66.5 kDa rHSA at high yield; the rice-seed delivery enables metric-ton-scale production without bioreactor CapEx, and the resulting rHSA is structurally and functionally identical to pHSA (identical N- and C-termini, no glycosylation, identical melting point 65°C, identical esterase activity and crystal structure).
   • InVitria’s Optibumin 25 — the first recombinant 25% HSA in closed-system bags — demonstrates the platform’s downstream performance: <0.5% total aggregates by SEC, ~99% Cys34 free thiol reduction across 10 production lots (vs ~60% in plasma HSA), single-peak homogeneity by IEX-HPLC, ~3-fold higher maleimide conjugation efficiency, and ~3-fold higher drug binding affinity (Kd 2.58 μM vs pHSA’s 7.45 μM).
2. Pichia pastoris yeast expression:
   • Pichia pastoris accounts for ~38.7% of global rHSA production on yield efficiency; Shilpa Medicare’s sRbumin® rHA 20% is produced via yeast fermentation at a large-scale facility after 8 years of development, with Phase 1 bioequivalence to Flexbumin (pdHSA) demonstrated across Cmax and AUC at 80-125% bioequivalence intervals, safe up to 40 g single dose and 70 g cumulative dose in 62 healthy volunteers.
   • Provis Biolabs (India) and Canvax (Spain) also produce Pichia pastoris rHSA — Provis at >98% purity (SDS-PAGE, HPLC) under ISO 9001:2015 / GMP certification — providing the smaller-scale research and RUO-grade supply that complements the larger therapeutic programs.
3. Hansenula polymorpha yeast expression:
   • Basic Pharma (NL) and ARTES Biotechnology (DE) use Hansenula polymorpha — a methylotrophic yeast with strong regulated promoters for high-density fermentation — to produce tag-free rHSA at >95% purity (RP-HPLC, SDS-PAGE), with the HSA gene inserted into the yeast genome for stable expression without antibiotic selection markers; the product is animal-component-free and peptide-tag-free, distinguishing it from research-grade E. coli rHSA.

07Value chains and production pipelines

Industrial pipeline of recombinant human serum albumin (FDA BLA & Novel Excipient / EU Centralised Procedure / NMPA biologics / CDSCO SEC India)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Strain & construct     │ ───> │ 2. Upstream expression    │
│    (rice endosperm,       │      │    (rice field/greenhouse │
│    Pichia, Hansenula,     │      │    or yeast bioreactor)   │
│    fungal)                │      │                           │
└───────────────────────────┘      └───────────────────────────┘
                                                  │
                                                  ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Chromatographic        │ <─── │ 3. Extraction &           │
│    purification           │      │    cell disruption        │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Stabilizer-free        │ ───> │ 6. Fill-finish & QC       │
│    formulation /          │      │    (closed-system bag,    │
│    lyophilization         │      │    vial, or bulk)         │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Strain & construct

The 585-amino-acid HSA gene is inserted into the host genome: rice endosperm expression cassette (Healthgen OryzHiExp, InVitria ExpressTec — both Oryza sativa), Pichia pastoris (Shilpa Medicare, Provis Biolabs, Canvax), Hansenula polymorpha (Basic Pharma / ARTES Biotechnology), or a precision-fermentation fungal cell line (Proliant AlbufreeDX); a master cell bank or stable rice seed line is established under GMP.

Stage 2: Upstream expression

Rice-based platforms proliferate the rHSA in rice endosperm cells through greenhouse or field cultivation (Healthgen’s rice molecular pharming), while yeast platforms run high-density fermentation in stainless or single-use bioreactors (Shilpa’s large-scale fermentation facility, Basic Pharma’s 50 L bioreactors, InVitria’s metric-ton-scalable Junction City Kansas cGMP facility); the rHSA accumulates intracellularly in yeast or in the rice seed storage compartment.

Stage 3: Extraction & cell disruption

Rice seeds are milled and the rHSA extracted from the endosperm (Healthgen’s OryzPur purification platform); yeast biomass is lysed mechanically or enzymatically to release the intracellular rHSA; the resulting crude lysate contains the 66.5 kDa rHSA plus host-cell proteins, nucleic acids, and cell debris.

Stage 4: Chromatographic purification

Affinity, ion-exchange and hydrophobic-interaction chromatography isolate rHSA from host-cell impurities; InVitria’s Optibumin 25 process achieves <0.5% total aggregates by high-resolution 3 μm SEC, single-peak homogeneity by IEX-HPLC with no detectable charge variants, and ~99% Cys34 free thiol reduction across 10 production lots; Basic Pharma achieves >95% purity (RP-HPLC, SDS-PAGE); Healthgen’s OryzPur meets USP/ChP purity standards.

Stage 5: Stabilizer-free formulation / lyophilization

The purified rHSA is formulated as a stabilizer-free aggregate-depleted native-state molecule (Optibumin 25, 250 mg/mL), a lyophilized powder (Exbumin 10 g / 100 g / 1 kg / bulk; ARTES / Basic Pharma lyophilized from water), or a 20% liquid solution (sRbumin®, Canvax 20% solution); the formulation step defines whether the product is excipient-grade (Exbumin for Merck ERVEBO), diagnostic-grade (AlbufreeDX), or therapeutic-grade (OsrHSA injection, sRbumin®).

Stage 6: Fill-finish & QC

Aseptic fill-finish yields finished rHSA as: sterile 25% liquid in 100 mL closed-system bags (Optibumin 25, 3-year shelf life at 2-8°C) for cell and gene therapy biomanufacturing; lyophilized vials (Exbumin, ARTES rHSA); 1-million-vial annual capacity OsrHSA Precise injection vials (Healthgen’s 70,000 m² cGMP facility, cold-chain distribution across 31 Chinese provinces); or bulk excipient-grade for vaccine and biologic formulation (ERVEBO at 0.25% intramuscular); each lot is released with Certificate of Analysis, Safety Data Sheet, Certificate of Origin, Animal-Free/TSE-BSE Statement, ISO 9001 certificate, and cGMP Statement to support IND/BLA and supplier qualification workflows.